

# Massimo Loda

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2238664/massimo-loda-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166  
papers

15,344  
citations

49  
h-index

123  
g-index

177  
ext. papers

18,869  
ext. citations

9.7  
avg, IF

6.04  
L-index

#	Paper	IF	Citations
166	O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage.. <i>Journal of Biomedical Science</i> , <b>2022</b> , 29, 13	13.3	0
165	Intra-epithelial non-canonical Activin A signaling safeguards prostate progenitor quiescence.. <i>EMBO Reports</i> , <b>2022</b> , e54049	6.5	0
164	Fatty acid synthase as a potential new therapeutic target for cervical cancer.. <i>Anais Da Academia Brasileira De Ciencias</i> , <b>2022</b> , 94, e20210670	1.4	1
163	A multidisciplinary approach to optimize primary prostate cancer biobanking.. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2022</b> , 40, 271.e1-271.e7	2.8	0
162	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.. <i>Nature Communications</i> , <b>2022</b> , 13, 2559	17.4	5
161	Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 894-894	2.2	
160	Exploring a role for fatty acid synthase in prostate cancer cell migration. <i>Small GTPases</i> , <b>2021</b> , 12, 265-272		5
159	Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. <i>Nature Communications</i> , <b>2021</b> , 12, 1660	17.4	60
158	EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , <b>2021</b> , 2, 444-456	15.4	37
157	Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 3372	17.4	3
156	Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer. <i>Prostate</i> , <b>2021</b> , 81, 50-57	4.2	14
155	Rapid Implementation of Severe Acute Respiratory Syndrome Coronavirus 2 Emergency Use Authorization RT-PCR Testing and Experience at an Academic Medical Institution. <i>Journal of Molecular Diagnostics</i> , <b>2021</b> , 23, 149-158	5.1	3
154	Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss. <i>Journal of Pathology</i> , <b>2021</b> , 253, 292-303	9.4	4
153	O-GlcNAc Transferase - An Auxiliary Factor or a Full-blown Oncogene?. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 555-564	6.6	8
152	Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 1000-1008	4	0
151	ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 1704-1718	10.1	16
150	Transcriptional landscape of PTEN loss in primary prostate cancer. <i>BMC Cancer</i> , <b>2021</b> , 21, 856	4.8	1

149	Inflammatory metabolic profile of South African patients with prostate cancer. <i>Cancer &amp; Metabolism</i> , <b>2021</b> , 9, 29	5.4	5
148	PKC $\zeta$ inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. <i>Molecular Cell</i> , <b>2021</b> , 81, 4509-4526.e10	17.6	3
147	Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. <i>RNA Biology</i> , <b>2021</b> , 1-8	4.8	4
146	The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic. <i>Academic Pathology</i> , <b>2021</b> , 8, 23742895211006818	1.3	2
145	Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> , 30, 751-756	4	0
144	Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Clinical Microbiology</i> , <b>2020</b> , 58,	9.7	38
143	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. <i>Carcinogenesis</i> , <b>2020</b> , 41, 904-908	4.6	1
142	SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays. <i>Clinica Chimica Acta</i> , <b>2020</b> , 509, 117-125	6.2	34
141	Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases. <i>Oncogene</i> , <b>2020</b> , 39, 3666-3679	9.2	17
140	Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. <i>Blood</i> , <b>2020</b> , 136, 1169-1179	2.2	581
139	Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9. <i>Molecular Cancer Research</i> , <b>2020</b> , 18, 1512-1521	6.6	17
138	Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. <i>European Urology</i> , <b>2020</b> , 78, 637-639	10.2	3
137	Phase I study of the Lu-DOTA-Tyr-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung <b>2020</b> , 8,		13
136	RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 20-21	2.2	
135	Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 111-111	2.2	4
134	Tumor protein expression of BRCA1 and development of lethal prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 65-65	2.2	
133	A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. <i>ELife</i> , <b>2020</b> , 9,	8.9	19
132	Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions <b>2020</b> ,		51

131	BCL9 provides multi-cellular communication properties in colorectal cancer by interacting with paraspeckle proteins. <i>Nature Communications</i> , <b>2020</b> , 11, 19	17.4	13
130	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1086-1093	12.9	10
129	Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. <i>Advanced Drug Delivery Reviews</i> , <b>2020</b> , 159, 245-293	18.5	96
128	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	795
127	SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. <i>Cancer Cell</i> , <b>2020</b> , 38, 661-671.e2	24.3	132
126	Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. <i>Cancer Prevention Research</i> , <b>2020</b> , 13, 979-988	3.2	1
125	Systematic Assessment of Tumor Purity and Its Clinical Implications. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	7
124	COVID-19 Viral and Serology Testing in New York City Health Care Workers. <i>American Journal of Clinical Pathology</i> , <b>2020</b> , 154, 592-595	1.9	7
123	Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5903-5913	12.9	4
122	Routine Laboratory Blood Tests Predict SARS-CoV-2 Infection Using Machine Learning. <i>Clinical Chemistry</i> , <b>2020</b> , 66, 1396-1404	5.5	44
121	Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. <i>European Urology Oncology</i> , <b>2019</b> , 2, 475-482	6.7	12
120	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. <i>Nature Communications</i> , <b>2019</b> , 10, 4358	17.4	50
119	Reply to Q1-STS, L-STS and KRJ-I are not authentic GEPNET cell linesQ <i>Nature Genetics</i> , <b>2019</b> , 51, 1427-1428	3.3	3
118	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11428-11436	11.5	383
117	When fat goes down, prostate cancer is on the ropes. <i>Molecular and Cellular Oncology</i> , <b>2019</b> , 6, 1595308	1.2	3
116	Aneuploidy drives lethal progression in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 11390-11395	11.5	46
115	AKT1 quiescent cancer cells in ductal carcinoma in situ of the breast. <i>Npj Breast Cancer</i> , <b>2019</b> , 5, 10	7.8	2
114	The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6916-6924	12.9	94

113	Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 317-317	2.2	1
112	Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 86-86	2.2	4
111	The Metabolic Landscape of Prostate Cancer. <i>European Urology Oncology</i> , <b>2019</b> , 2, 28-36	6.7	33
110	Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 1155-1165	6.6	28
109	A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 2047-2054	4	5
108	Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 631-640	11.5	110
107	Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 76, 89-97	10.2	98
106	Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 446-456	6.6	22
105	Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. <i>Eur Urol</i> 2018;73:961-7. <i>European Urology</i> , <b>2019</b> , 75, e54-e55	10.2	
104	LSD1: A single target to combat lineage plasticity in lethal prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 4530-4531	11.5	13
103	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. <i>Carcinogenesis</i> , <b>2018</b> , 39, 1431-1437	4.6	26
102	A Prospective Study of Aspirin Use and Prostate Cancer Risk by Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2018</b> , 27, 1231-1233	4	1
101	Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. <i>Cancer Research</i> , <b>2018</b> , 78, 4716-4730	10.1	33
100	Association of low PTEN expression by fluorescence immunohistochemistry (F-IHC) and lethal disease in men with surgically-treated prostate cancer (PrCa).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 15-15	2.2	0
99	Clinical outcomes with cumulative tumor suppressor gene (TSG) alterations in castration sensitive (CSPC) and resistant (CRPC) prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5055-5055	2.2	
98	AKT1 Quiescent Cancer Cells Promote Solid Tumor Growth. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 254-263	6.1	7
97	Height, Obesity, and the Risk of -Defined Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2018</b> , 27, 193-200	4	11
96	Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2018</b> , 8,	5.4	30

95	MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2018</b> , 27, 201-207	4	18
94	Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration. <i>IScience</i> , <b>2018</b> , 9, 451-460	6.1	36
93	Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 12812-12824	3.3	7
92	Specific F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone-Binding Globulin. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 1538-1543	8.9	4
91	Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG. <i>Prostate</i> , <b>2017</b> , 77, 647-653	4.2	8
90	Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. <i>Science</i> , <b>2017</b> , 355, 78-83	33.3	492
89	Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 281-293	6.6	15
88	Metabolic Profiling in Formalin-Fixed and Paraffin-Embedded Prostate Cancer Tissues. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 439-447	6.6	38
87	Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 470, 711-715	5.1	10
86	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E5207-E5215	11.5	155
85	Association of Tissue Abiraterone Levels and Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4592-4601	12.9	25
84	ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes. <i>Cancer Biomarkers</i> , <b>2017</b> , 18, 215-220	3.8	3
83	Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. <i>Cancer Discovery</i> , <b>2017</b> , 7, 202-217	24.4	38
82	Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. <i>BMC Cancer</i> , <b>2017</b> , 17, 494	4.8	16
81	Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6812-6822	12.9	58
80	Persistence of AKT1 low quiescent cancer cells after neoadjuvant chemotherapy in triple negative breast cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11579-11579	2.2	
79	MicroRNA MIR21 and T Cells in Colorectal Cancer. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 33-40	12.5	22
78	Challenging Roadblocks to Cancer Cure. <i>Cancer Research</i> , <b>2016</b> , 76, 4924-30	10.1	3

77	Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2520-7	5.6	23
76	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. <i>American Journal of Clinical Nutrition</i> , <b>2016</b> , 103, 851-60	7	56
75	Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 939-44	8.7	16
74	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 352-9	3.3	21
73	The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women. <i>Cancer Research</i> , <b>2016</b> , 76, 1926-34	10.1	30
72	Overexpression of the Long Non-coding RNA SchLAP1 Independently Predicts Lethal Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 549-552	10.2	98
71	Precision prevention of TMPRSS2:ERG prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 78-78	2.2	
70	Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes have it!. <i>Histopathology</i> , <b>2016</b> , 68, 303-7	7.3	4
69	Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. <i>Cancer Causes and Control</i> , <b>2016</b> , 27, 1043-7	2.8	4
68	The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. <i>Cancer &amp; Metabolism</i> , <b>2016</b> , 4, 22	5.4	20
67	Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 745-9	4	14
66	Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 396-404	12.9	88
65	Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 1021-34	10.1	57
64	A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, 113-23	3.3	32
63	Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 1059-72	6.6	133
62	Molecular differences in transition zone and peripheral zone prostate tumors. <i>Carcinogenesis</i> , <b>2015</b> , 36, 632-8	4.6	23
61	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , <b>2015</b> , 17, 374-81	5.1	18
60	Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. <i>Nature Communications</i> , <b>2015</b> , 6, 6169	17.4	185

59	Tumor expression of adiponectin receptor 2 and lethal prostate cancer. <i>Carcinogenesis</i> , <b>2015</b> , 36, 639-474.6	17
58	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5277-85	12.9 129
57	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , <b>2015</b> , 163, 1011-25	56.2 1713
56	The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. <i>Nature Genetics</i> , <b>2015</b> , 47, 1346-51	36.3 226
55	Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 1431-40	6.6 15
54	Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1273-80	12.9 129
53	Association of prostate cancer risk variants with gene expression in normal and tumor tissue. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 255-60	4 69
52	HER2 as a target in invasive urothelial carcinoma. <i>Cancer Medicine</i> , <b>2015</b> , 4, 844-52	4.8 31
51	A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. <i>EBioMedicine</i> , <b>2015</b> , 2, 1957-64	8.8 43
50	Innovation in metabolomics to improve personalized healthcare. <i>Annals of the New York Academy of Sciences</i> , <b>2015</b> , 1346, 57-62	6.5 44
49	Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. <i>Prostate</i> , <b>2015</b> , 75, 1926-33	4.2 7
48	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , <b>2015</b> , 161, 1215-1228	56.2 1765
47	Advanced neuroendocrine prostate tumors regress to stemness. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 14406-7	11.5 11
46	Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer. <i>Molecular and Cellular Oncology</i> , <b>2015</b> , 2, e1001197	1.2 5
45	A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 274-274	2.2 6
44	miR125 and miR200a as potential circulating miRNA biomarkers in metastatic urothelial carcinoma patients treated with docetaxel.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 364-364	2.2 1
43	Discovery and validation of a 30-gene expression signature to identify prostate cancer patients who are candidates for active surveillance.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 10-10	2.2
42	Genomic landscape of high-grade T1 micropapillary bladder tumors.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 299-299	2.2



41	Application of a robust and novel ex vivo platform mimicking patient heterogenous tumor microenvironment for personalized cancer treatment.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6029-6029 <sup>2.2</sup>		
40	Association of SLCO transport genes with intraprostatic abiraterone (ABI) levels and pathologic outcomes in men with high-risk localized prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5013-5013	2.2	1
39	Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. <i>Nature Biotechnology</i> , <b>2014</b> , 32, 479-84	44.5	434
38	Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 2027-31	4	21
37	Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3705-15	2.2	169
36	Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. <i>Cancer Discovery</i> , <b>2014</b> , 4, 896-904	24.4	75
35	AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 7198-204	10.1	95
34	De novo fatty acid synthesis at the mitotic exit is required to complete cellular division. <i>Cell Cycle</i> , <b>2014</b> , 13, 859-68	4.7	48
33	5 $\alpha$ Reductase inhibitors and risk of high-grade or lethal prostate cancer. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 1301-7	11.5	32
32	Effect of HOXB13 and FOXA1 on the AR cistrome during prostate tumorigenesis in primary human tissue.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5018-5018	2.2	1
31	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. <i>Nature Genetics</i> , <b>2013</b> , 45, 747-55	36.3	121
30	Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. <i>Cancer Discovery</i> , <b>2013</b> , 3, 44-51	24.4	40
29	Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 260-260	2.2	
28	The Metabolic Fingerprints of Prostate Cancer. <i>FASEB Journal</i> , <b>2013</b> , 27, 471.9	0.9	
27	SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. <i>Nature</i> , <b>2011</b> , 470, 269-73	50.4	383
26	TUMOR BIOLOGY <b>2011</b> , 133-157		
25	Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1001204	6	70
24	A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 11002-7	11.5	54

23	Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 519-32	9.7	293
22	Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. <i>Nature</i> , <b>2008</b> , 454, 776-80	9.4	599
21	Cohort study of fatty acid synthase expression and patient survival in colon cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5713-20	2.2	133
20	Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 2557-65	7.5	122
19	Quantum Dot Based Duplex In Situ Hybridisation for Gene Expression Profiling.. <i>Blood</i> , <b>2005</b> , 106, 3265-3265		
18	Fatty acid synthase: a metabolic oncogene in prostate cancer?. <i>Journal of Cellular Biochemistry</i> , <b>2004</b> , 91, 47-53	4.7	231
17	Frequent HIN-1 Promoter Methylation and Lack of Expression in Multiple Human Tumor Types. <i>Molecular Cancer Research</i> , <b>2004</b> , 2, 489-494	6.6	33
16	Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. <i>Molecular Cancer Research</i> , <b>2003</b> , 1, 707-15	6.6	192
15	PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER. <i>Journal of Urology</i> , <b>2002</b> , 167, 1392-1392	2.5	5
14	The de-ubiquitinating enzyme Unp interacts with the retinoblastoma protein. <i>Oncogene</i> , <b>2001</b> , 20, 5538-42	4.2	28
13	Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. <i>Modern Pathology</i> , <b>2001</b> , 14, 437-42	9.8	53
12	Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. <i>Genes Chromosomes and Cancer</i> , <b>2000</b> , 27, 95-103	5	87
11	Detection of TCR-gamma gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. <i>Journal of Cutaneous Pathology</i> , <b>2000</b> , 27, 228-34	1.7	45
10	Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. <i>Nature</i> , <b>2000</b> , 404, 407-11	50.4	720
9	Her-2-neu expression and progression toward androgen independence in human prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 1918-25	9.7	288
8	p63 is a prostate basal cell marker and is required for prostate development. <i>American Journal of Pathology</i> , <b>2000</b> , 157, 1769-75	5.8	470
7	Thymosin beta15 expression in tumor cell lines with varying metastatic potential. <i>Clinical and Experimental Metastasis</i> , <b>1998</b> , 16, 227-33	4.7	40
6	Role of p27 in prostate carcinogenesis. <i>Cancer and Metastasis Reviews</i> , <b>1998</b> , 17, 337-44	9.6	59

5	Mitogen-activated protein kinases and apoptosis in PIN. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>1998</b> , 432, 407-13	5.1	46
4	LOW P27 EXPRESSION PREDICTS POOR DISEASE-FREE SURVIVAL IN PATIENTS WITH PROSTATE CANCER. <i>Journal of Urology</i> , <b>1998</b> , 159, 941-945	2.5	263
3	Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. <i>Nature Medicine</i> , <b>1997</b> , 3, 231-4	50.5	903
2	Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. <i>Nature Medicine</i> , <b>1996</b> , 2, 1322-8	50.5	131
1	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets		1